Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus by Kirn, David H et al.
Targeting of Interferon-Beta to Produce
a Specific, Multi-Mechanistic Oncolytic
Vaccinia Virus
David H. Kirn
1,2, Yaohe Wang
3, Fabrice Le Boeuf
4, John Bell
4, Steve H. Thorne
1,5¤*
1 Jennerex Biotherapeutics, San Francisco, California, United States of America, 2 Clinical Pharmacology, University of Oxford, Oxford, United Kingdom, 3 Cancer Research UK
Molecular Oncology Centre, Queen Mary’s School of Medicine and Dentistry, Charterhouse Square, London, United Kingdom, 4 Ottawa Health Research Institute, Ottawa,
Ontario, Canada, 5 Department of Pediatrics and Bio-X Program, Stanford University, Stanford, California, United States of America
Funding: This work was funded in
part by the National Cancer Institute
In vivo Molecular Imaging Center at
Stanford grant (P50 CA114747) and
the John A and Cynthia Fry Gunn
Research Fund. The funders had no
role in study design, data collection or
analysis or in the decision to publish
or the preparation of the manuscript.
Competing Interests: DHK, FLB, JB,
and SHT all declare a financial interest
in Jennerex Biotherapeutics, Inc. SHT
is a shareholder; FLB receives a
portion of his salary from Jennerex, JB
sits on the Board of Directors, and
DHK is President and CEO of Jennerex.
JB is Director of the Canadian
Oncolytic Virus Consortium and hold
grants from the National Cancer
Institute of Canada directed towards
the discovery and, ultimately, clinical
testing of oncolytic viruses. JB’s host
institute (Ottawa Health Research
Institute [OHRI]) is an equity holder in
Jennerex ULC.
Academic Editor: Grant McFadden,
University of Florida, United States of
America
Citation: Kirn DH, Wang Y, Le Boeuf F,
Bell J, Thorne SH (2007) Targeting of
interferon-beta to produce a specific,
multi-mechanistic oncolytic vaccinia
virus. 4(12): e353. doi:10.1371/journal.
pmed.0040353
Received: May 29, 2007
Accepted: October 30, 2007
Published: December 27, 2007
Copyright:  2007 Kirn et al. This is
an open-access article distributed
under the terms of the Creative
Commons Attribution License, which
permits unrestricted use, distribution,
and reproduction in any medium,
provided the original author and
source are credited.
Abbreviations: CTL, cytotoxic T
lymphocyte; GFP, green fluorescent
protein; LPS, lipopolysaccharide;
mIFN-b, murine interferon-beta; MOI,
multiplicity of infection; MV, myxoma
virus; NHBE cell, normal human
bronchial epithelial cell; PFU, plaque-
forming unit; SAEC, small airway
epithelial cell; WR, Western Reserve
* To whom correspondence should be
addressed. E-mail: thornesh@upmc.
edu
¤ Current address: Division of Surgical
Oncology, University of Pittsburgh,
Pittsburgh, Pennsylvania, United
States of America
ABSTRACT
Background
Oncolytic viruses hold much promise for clinical treatment of many cancers, but a lack of
systemic delivery and insufficient tumor cell killing have limited their usefulness. We have
previously demonstrated that vaccinia virus strains are capable of systemic delivery to tumors
in mouse models, but infection of normal tissues remains an issue. We hypothesized that
interferon-beta (IFN-b) expression from an oncolytic vaccinia strain incapable of responding to
this cytokine would have dual benefits as a cancer therapeutic: increased anticancer effects and
enhanced virus inactivation in normal tissues. We report the construction and preclinical
testing of this virus.
Methods and Findings
In vitro screening of viral strains by cytotoxicity and replication assay was coupled to cellular
characterization by phospho-flow cytometry in order to select a novel oncolytic vaccinia virus.
This virus was then examined in vivo in mouse models by non-invasive imaging techniques. A
vaccinia B18R deletion mutant was selected as the backbone for IFN-b expression, because the
B18R gene product neutralizes secreted type-I IFNs. The oncolytic B18R deletion mutant
demonstrated IFN-dependent cancer selectivity and efficacy in vitro, and tumor targeting and
efficacy in mouse models in vivo. Both tumor cells and tumor-associated vascular endothelial
cells were targeted. Complete tumor responses in preclinical models were accompanied by
immune-mediated protection against tumor rechallenge. Cancer selectivity was also
demonstrated in primary human tumor explant tissues and adjacent normal tissues. The IFN-
b gene was then cloned into the thymidine kinase (TK) region of this virus to create JX-795 (TK
 /
B18R
 /IFN-b
þ). JX-795 had superior tumor selectivity and systemic intravenous efficacy when
compared with the TK
 /B18R
  control or wild-type vaccinia in preclinical models.
Conclusions
By combining IFN-dependent cancer selectivity with IFN-b expression to optimize both
anticancer effects and normal tissue antiviral effects, we were able to achieve, to our
knowledge for the first time, tumor-specific replication, IFN-b gene expression, and efficacy
following systemic delivery in preclinical models.
The Editors’ Summary of this article follows the references.
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Oncolytic viruses have promise as cancer therapeutics due
to their targeted nature and ability to destroy cancer cells
through novel mechanisms-of-action (oncolysis and/or ne-
crosis) [1–3]. Selective intratumoral replication of the virus
leads to viral multiplication and spread to adjacent cancer
cells and subsequent lysis of all infected cancer cells. One
targeting strategy that has proven successful in a variety of
oncolytic strains involves deletions of viral anti–type-I
interferon (IFN) gene products. Cancer selectivity results
through IFN-mediated inhibition of replication in normal
tissues, whereas replication and oncolysis proceeds unhin-
dered in tumor cells with defects in IFN responses [4–7].
Examples include mutations of the M-protein genes in
vesicular stomatitis virus (VSV), the gamma-34.5 genes in
herpes simplex virus (HSV), and viral-associated (VA) RNA in
adenovirus. In addition, a variety of unmodiﬁed small RNA
viruses have demonstrated natural tumor tropism mediated
by their inherent sensitivity to the interferon-mediated
antiviral state in normal cells [4,8,9].
Oncolytic viruses can further be engineered to express
therapeutic transgene products that can destroy tumors
through diverse and complementary mechanisms [10,11].
One such transgene, IFN-b, has multiple anticancer effects,
including direct antiproliferative effects [12], the induction of
tumor-speciﬁc cytotoxic T lymphocytes (CTL) [13], and
antiangiogenic effects [14]. IFN-b protein therapy is approved
for use in recurrent multiple sclerosis [15] and phase I–II
clinical trials have been performed with IFN-b in patients with
brain tumors and other metastatic solid tumors [16]. However,
overall efﬁcacy was limited and transient, and signiﬁcant
systemic toxicities limited further dose escalation [17].
We hypothesized that expression of IFN-b from an
oncolytic virus would have dual beneﬁts by increasing
anticancer efﬁcacy and increasing safety. Although IFN-b in
normal tissues inhibits viral replication [18], tumor cells are
commonly resistant to the antiviral effects of type-I IFNs;
oncolytic virus replication should therefore not be inhibited
in these IFN-resistant cancer cells. Nevertheless, IFN-b–
mediated anticancer effects, including the induction of
tumor-speciﬁc CTL and antiangiogenic effects should still
be operative. In order to achieve safe, sustained, high-level
expression of IFN-b selectively in tumor tissue, we engineered
IFN-b expression from a tumor-selective oncolytic vaccinia
virus. Expression of IFN-b required a novel approach,
however, because vaccinia expresses multiple gene products
that block type-I IFN responses [19,20]. Of particular
importance, vaccinia expresses a secreted inhibitor of type-I
IFN designated B18R [21,22]. We hypothesized that deletion
of B18R would be necessary to allow expressed IFN-b to
function effectively, and that deletion of this gene could also
lead to enhanced tumor selectivity.
Methods
Viruses and Cell Lines
Vaccinia strain Western Reserve (WR) was purchased from
ATCC. The B18R-deleted strain of WR was kindly provided
by Professor Geoff Smith (Imperial College, London, United
Kingdom). B18R, thymidine kinase (TK) double-deleted viruses
were constructed by insertion of DNA into the vaccinia TK
gene by homologous recombination. The cloning plasmid
pSC65 (provided by Professor Bernie Moss, National Insti-
tutes of Health) was remade so that the ﬁreﬂy luciferase gene
was expressed from the pSE/L promoter and, for JX-795, the
murine beta-interferon (mIFN-b) cDNA was cloned for
expression from the p7.5 early/late promoter. The mIFN-b
cDNA was provided by Mike Parr (Biogen-Idec). Successful
recombination events were selected for by luciferase expres-
sion, and correct insertion of plaque-puriﬁed clones was
veriﬁed by PCR. Recombination (producing TK inactivation)
was performed into both B18R-deleted virus or WR, using
vectors expressing luciferase alone, or luciferase and mIFN-b.
Myxoma virus (strain Lausanne) (MV) was kindly provided by
Professor Grant McFadden (University of Florida).
Primary human cells (small airway epithelial cells [SAECs]
and normal human bronchial epithelial cells [NHBEs]) were
purchased from Clonetics (Lonza Biosciences); C33A, A2780,
and HCT 116 human tumor cell lines, BSC-1 (monkey kidney
cells), and NIH 3T3 murine cell lines were purchased from
ATCC and CMT-93; JC and CMT-64 (murine tumor cell line)
were provided by Cancer Research UK cell bank collection.
In Vitro Replication, Viability, Bioluminescence, and ELISA
Assays
Cells were treated with human IFN-a (50 U/ml; SIGMA) in
six-well plates either 24 h prior to or 5 h postinfection with
different viruses. Viruses were added at a multiplicity of
infection (MOI) of 1.0 viral plaque forming unit (PFU)/cell.
Virus (from cells and medium) was collected 72 h later (unless
otherwise indicated) and titered after three rounds of
freezing and thawing on BSC-1 cells by plaque assay.
In cell viability assays, serial dilutions of virus were added
to cells in 96-well plates, and IFN-a was added 5 h later. Cell
viability was determined 72 h later by MTS assay (Promega),
and viral MOI required to reduce cell viability to 50%
effective concentration (EC50) (relative to untreated controls
[100%] or cell-free wells [0%]) was determined from a
standard curve.
Bioluminescence assays were performed following infection
of cell layers in six-well plates at an MOI of 1.0 or 0.05 with
viral strains expressing ﬁreﬂy luciferase. After 24h, luciferin
substrate (30 mg/ml; Caliper) was added to the wells and
bioluminescence determined in an IVIS50 system (Caliper).
ELISA for murine IFN-b was performed following infection
of cell layers in six-well plates at an MOI of 1.0 PFU/ml with
viral strains expressing mIFN-b. Every hour after infection,
the medium was changed, and the spent medium spun (300g,
5 min) to remove dead cells, and retained to quantify mIFN-b
produced within the previous hour. ELISA for mIFN-b
(Bioscource) was performed according to the manufacturer’s
instructions.
ELISA for human IFN-b was performed following treat-
ment of cell layers in six-well plates with lipopolysaccharide
(LPS; 5lg/ml), or infection with viruses (modiﬁed vaccinia
virus Ankara [MVA] or WR-delB18R) at an MOI of 1.0 PFU/ml.
Medium was collected 18 h after treatment, ﬁltered (0.22 lm)
to remove cells or virus, and ELISA (Fujirebio) run according
to the manufacturer’s instructions.
Flow Cytometry
Cells were grown in six-well plates, before human IFN-b
was added (100 U/ml; SIGMA). Fifteen minutes later, cells
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scraped, washed and permeabilized in 100% methanol,
before a second wash. Cells were stained with rabbit anti-
phospho-STAT1 (Tyr701; Cell Signaling Technology), with an
APC-labeled secondary, and samples run on a FACScaliber
(Becton Dickinson).
Explant Preparation, Culture, and Infection
Fresh tumor and adjacent normal tissue specimens were
sliced into approximately 2-mm
3 pieces and placed on a
Surgifoam sponge that was presoaked with alpha medium
containing 10% fetal bovine serum. B18R and TK gene–
deleted vaccinia virus encoding green ﬂuorescent protein
(GFP) was then added directly to the specimen (1 3 10
7 PFU)
and allowed to infect for 2 h at 37 8C before covering the
sponge and specimen with medium containing serum. At 48
h, specimens were visualized using ﬂuorescence microscopy.
In Vivo Biodistribution, Bioluminescence, and Efficacy
Assays
Tumors were formed by subcutaneous implantation of
syngeneic tumor cells into immunocompetent mice. A total of
5310
5 CMT-93 or JC tumor cells were implanted into C57/B6
or BALB/c mice respectively. Tumors were allowed to form
for 10–14 d (until they reached 50–100 mm
3 as determined by
caliper measurements), animals were then regrouped and
treated with a single intravenous (tail vein) or intratumoral
injection of 1 3 10
8 PFU of virus (unless otherwise stated).
During the biodistribution studies, animals were sacriﬁced at
indicated times after treatment; organs were recovered and
snap frozen. Organs were then homogenized and viral titers
determined by plaque assay on BSC-1 cells.
In some experiments, animals were treated with virus
expressing ﬁreﬂy luciferase. Animals were imaged using an
IVIS100 system (Caliper) 5 min after intraperitoneal injection
of 150 mg/kg luciferin (Caliper). Animals were anesthetized
with 2% isoﬂurane. Regions of interest were drawn around
the whole animal and the tumor, and light output determined
using the LivingImage software (Caliper). Light output for the
torso was determined as the whole-body signal minus the
tumor signal.
In the efﬁcacy experiments, tumor burden was determined
by caliper measurement at indicated times after treatment,
and animals sacriﬁced once tumors reached 1,500 mm
3.
Survival curves (Kaplan-Meier) were plotted.
All animal studies were performed under a UK project
license, or with US Institutional Animal Care and Use
Committee (IACUC) approval.
Ultrasound Analysis of Tumor Vasculature
Mice bearing subcutaneous JC tumors implanted onto the
ﬂank were imaged using the Vevo770 small-animal ultra-
sound system (VisualSonics) during the delivery of a 100-ll
bolus of Vevo MicroMarker nontargeted contrast agent
(VisualSonics) through the tail vein. Reference data collected
prior to delivery of the contrast agent was used to determine
areas of blood ﬂow within the tumor.
Ex Vivo Immunohistochemistry, Immunofluorescence, and
ELISA
Some animals bearing subcutaneous tumors and treated
with different viruses (as above) were sacriﬁced and their
tumors ﬁxed in paraformaldehyde, embedded in parafﬁn,
sectioned (5 lm), and then stained for immunohistochemis-
try. A polyclonal anti-vaccinia or a monoclonal anti-mouse
CD3 antibody was used to detect viral-infected cells or CD3-
positive cells, and visualized using horseradish peroxidase
(DAKO). As a control, vaccinia strain WR was UV-inactivated
following treatment with psoralen, and then column puriﬁed.
In similar experiments, tumors treated with vaccinia strains
expressing GFP were frozen in optimal temperature control
(OTC) compound, sectioned (10 lm), ﬁxed in acetone, and
stained with anti-CD31 antibody conjugated to phycoerythrin
(PE; BD Pharmigen). GFP and PE ﬂuorescence was examined
on a Leica Confocal microscope.
ELISA was also run to detect mIFN-b on serum collected by
retino-orbital bleeding, or from tumor tissue. Tumor tissue
was weighed, homogenized, and then cleared by gentle
centrifugation before ELISA for mIFN-b (Biosource).
Statistical Analyses
Kaplan-Meier curves were compared using the log rank
test. Analyses of all other data were performed using a
Student t-test.
Results
In Vitro Tumor Selectivity of a B18R Gene-Deleted Vaccinia
(WR-delB18R)
Because a variety of viral strains unable to, or deleted in
their ability to, interfere with the type-I IFN response are also
tumor targeting, we hypothesized that vaccinia strains
containing deletions in genes acting on this pathway would
also display tumor-speciﬁc replication. We therefore
screened WR and a strain of WR vaccinia virus containing a
deletion in the B18R gene (WR-delB18R) against several
human cancer cell lines and primary cells. The B18R gene
product is a secreted or membrane-bound type-I IFN-binding
protein that is known to block the protective effects of type-I
IFN on vaccinia-infected cells and whose deletion increases
the median lethal dose (LD50) of the virus by more than three
logs [22]. It is therefore capable of binding and inactivating
type-I IFN that has been secreted from infected and/or
adjacent cells, and thereby prevents both the induction of an
antiviral state in surrounding cells, and induction of an
antiviral immune response. It was found that addition of
type-I IFN (human IFN-a) to the primary cells prior to
infection induced an antiviral state in these cells and limited
viral replication in a one-step replication study (Figure 1A).
However, addition of the IFN after viral infection was only
effective in producing an antiviral state in the B18R-deleted
strain, which was unable to inhibit the extracellular cytokine
(p ¼ 0.0055 for SAECs and 0.0012 for NHBEs). When the
tumor cell lines C33A and A2780 were similarly treated, no
effect of IFN addition was seen under any conditions,
implying an inability of these cells to respond to this cytokine
(Figure 1B). In HCT 116 cells, however, it was found that
addition of IFN-b postinfection was capable of reducing
replication of the B18R-deleted strain (WR-delB18R) relative
to WR.
It was similarly demonstrated that IFN addition post-
infection with WR-delB18R could also protect primary cells,
but not IFN-resistant tumor cells, from viral-mediated cell
killing (Figure 1C) and that this effect was dependent on loss
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selectivity and therapeutic index of vaccinia in vitro through
B18R deletion.
The precise nature of any dysfunction in IFN signaling in
the A2780 and C33A cells and their response to viral
exposure were also investigated and compared to the NHBE
and HCT 116 cell lines. Although HCT 116 has previously
been reported to be capable of responding to type-I IFN [23],
this response was not in the context of an antiviral response.
The ability of these cell lines to produce, or respond to, IFN-b
was therefore examined (Figure 2). IFN-b production in the
presence of a viral pathogen may be in response to stimuli
from within an infected cell (typically through PKR induction
by dsRNA for DNA viruses), or external stimuli (typically
detected through binding to Toll Like Receptors (TLR)).
Primary cells (NHBEs) were found to up-regulate IFN-b
secretion in response to either MV infection (which has
previously been demonstrated to produce IFN-b upon
infection of human ﬁbroblasts, probably through PKR
activation [24]) or following exposure to LPS (which, along
with viral glycolipids, binds to and activates TLR4) (Figure
2A). However, NHBEs did not produce IFN-b above back-
ground levels when infected with WR-delB18R (Figure 2A).
This lack of IFN-b production is not surprising because
vaccinia expresses several genes that interfere with PKR
activation and signaling (e.g., E3L and K3L). It was further
found that A2780 cells could also increase IFN-b production
in response to either MV infection or LPS exposure (but not
to WR-delB18R infection); that HCT 116 could respond to
LPS exposure, but could not respond to MV infection; and
that C33A was unable to increase IFN-b production under
any of the conditions examined.
The ability of these cells to respond to IFN-b addition was
also examined through phosphorylation of STAT1, an
integral step in the signaling pathway following binding of
type-I IFNs to their receptor (Figure 2B). NHBEs were found
to be able to respond to IFN-b exposure, as were HCT 116
cells; however, A2780 cells, although able to produce IFN-b,
were unable to respond to it. It therefore appears that (1) all
vaccinia-infected cells are blocked in their ability to produce
type-I IFN directly (even though both NHBEs and A2780 can
produce type-I IFN in response to infection with the related
MV); (2) C33A is unable to produce IFN in response to TLR
activation; and (3) A2780 cells are unable to respond directly
to type-I IFN. The ability of different tumor and normal cells
to produce or respond to type-I IFN is therefore closely
associated to their ability to replicate the B18R-deleted virus.
Selectivity and Efficacy of the B18R Deletion Mutant In
Vivo
Immunocompetent mice bearing syngeneic subcutaneous
tumors were treated with sublethal doses (1 3 10
8 PFU) of
w i l d - t y p eW Ro rWR-delB18R b yas i n g l ei n t r a v e n o u s
injection (the B18R gene product is known to bind both
murine and human type-I IFNs [22]). Animals were sacriﬁced
at times post-treatment, and infectious virus recovered from
different organs was titered (Figure 3A). The B18R-deleted
strain was rapidly cleared from all tissues other than the
Figure 1. Effect of Type-I IFN on Replication of Vaccinia Strains in Tumor and Normal Cell Lines
(A) Primary human cell lines (SAECs and NHBEs) were grown to 50% confluence in six-well plates and treated with human IFN-a (50 U/ml) either 24 h
prior to or 5 h after infection with vaccinia (or else PBS was used as a control). Vaccinia strains WR (white bars) or WR-delB18R (WR with deletion of the
B18R gene; black bars) were used at an MOI of 1.0 PFU/cell. After 72 h, viral titers in the wells were determined by plaque assay (Student t-test for WR
versus WR-delB18R with IFN treatment postinfection, p ¼ 0.0055 for SAECs and 0.0012 for NHBEs).
(B) This assay was repeated using human tumor cell lines C33A, A2780, and HCT 116.
(C) Serial dilutions of vaccinia strains were added to cells (NHBE or A2780) 5 h before addition of human IFN-alpha (or PBS) as before. Cell viability in the
different wells was determined 72 h later by MTS assay, and EC50 values (viral PFU/ml required to reduce cell viability to 50% of untreated well) were
determined.
An asterisk (*) indicates significant difference (p ¼ 0.0055 for SAECs and 0.0012 for NHBEs).
doi:10.1371/journal.pmed.0040353.g001
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WR virus for the duration of the study (Figure 3B). Of
particular note, no B18R-deleted virus was recovered from
the brain at any time point.
Efﬁcacy of WR-delB18R as a single agent was also tested
following intratumoral or intravenous delivery (Figure 3C). A
dose-dependent response to intratumoral injection was seen,
with a single injection of 1 3 10
8 PFU of virus, resulting in
100% complete responses. This same dose given intra-
venously was also capable of producing signiﬁcant improve-
ments in survival over control animals (p ¼ 0.0047) and some
complete responses, but in a smaller number of the treated
mice. Higher doses, though feasible, were not tested.
Multi-Mechanistic Tumor Killing by WR-delB18R Vaccinia
Virus
It was hypothesized that immune-mediated destruction of
infected tumor cells may help enhance the oncolytic effect of
the virus. As such, it was noted that a signiﬁcant increase in
the numbers of tumor-inﬁltrating lymphocytes was seen in all
animals treated with replication-competent viruses (p¼0.035)
(Figure 4A). In addition, animals that had undergone
complete responses in Figure 3C, when rechallenged with
the same tumor cell line, were able to reject the tumor
implant, implying that infected tumor cells may be capable of
cross-presenting tumor antigens and thereby elicit a protec-
tive antitumor immune response (Figure 4B).
Finally, we noted that intravenously delivered virus
infected not only tumor cells initially, but also tumor vascular
endothelial cells (Figure 4C), resulting in viral gene expres-
sion in and around the endothelial cells. It is likely that
infection would lead to destruction of the infected tumor
endothelial cells, with resultant intravascular thrombosis and
vascular collapse within the tumor mass. The infection and
subsequent destruction of tumor endothelial cells was seen as
a loss of vascular density in a treated animal within 48 h of
intravenous delivery of WR-delB18R (Figure 4D). This tumor-
associated vascular targeting may represent a previously
undescribed mechanism of tumor destruction mediated by
the B18R-deleted strain and, presumably, other vaccinia
strains. Of note, this ﬁnding was not observed in any of the
normal organ vasculatures assessed histologically.
Selectivity of the B18R Deletion in Human Tumor Explant
Tissue
In order to establish whether the tumor-targeting potential
of the B18R deletion was also relevant in primary tumor
tissue, infection of explant tissues was examined. For this
work, the GFP gene was inserted into the viral TK gene of
WR-delB18R in order to track viral infection and gene
expression. The TK gene was chosen both because standard
cloning strategies exist to target it, and because the TK gene
deletion is itself tumor targeting [25]. It was clearly seen that
this virus was capable of successfully infecting several tumor
types, but was incapable of gene expression from either
normal liver or colorectal tissue (Figure 5). Whereas only
background level of virus (1310
3 PFU/g) was recovered from
the normal liver tissue after 48 h, 1310
8 PFU/g was recovered
from the colon tumor metastasis in the adjacent tissue
(unpublished data), indicating the GFP gene expression
translates to successful viral replication.
Characterization of the IFN-b–Expressing TK
 /B18R
 
Vaccinia Mutant (JX-795) In Vitro
Because the vaccinia B18R gene product normally binds
and removes secreted type-I IFNs, including IFN-b,aB18R
deletion mutant would be the optimal vaccinia strain to
express this cytokine. We constructed a cassette containing
the murine IFN-b gene and the ﬁreﬂy luciferase gene under the
control of the vaccinia p7.5 and pSE/L promoters, respec-
tively. This cassette was inserted by homologous recombina-
tion into the viral TK gene of WR-delB18R.
Signiﬁcant levels of IFN-b expression appeared within 5 h
after infection of a tumor cell monolayer, and reached a
plateau by 11 h postinfection; the plateau concentration was
approximately 10-fold higher than at 5 h (Figure 6A). These
Figure 2. Dysfunction in Type-I IFN Production or Signaling in Normal and Tumor Cell Lines
(A) Production of IFN-b. Cell lines (NHBEs, HCT 116, C33A, and A2780) were infected with MV or WR-delB18R at an MOI of 5.0, or treated with LPS at 5 lg/
ml; medium was collected after 18 h, and IFN-b levels determined by ELISA.
(B) Response to IFN-b. Cell lines (NHBEs, HCT 116, and A2780) were treated with IFN-b (blue graphs) or PBS (red graphs), and fixed and permeabilized 15
min later. Levels of phospho-STAT1 were determined by flow cytometry.
doi:10.1371/journal.pmed.0040353.g002
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as would be expected with the vaccinia p7.5 early/late
promoter driving gene expression [26]. This implies that
high levels of gene expression are linked to replication of the
viral genome, and therefore will not occur efﬁciently during
infection of resistant normal cell types. This adds an extra
layer of safety, as expression from viral early/late promoters
allows for low levels of gene expression early in infection,
even during infection of cells that do not support viral
replication. This allows normal tissues to mount a type-I IFN–
dependent antiviral response early after exposure to virus,
thus preventing high-level late gene expression leading to
IFN-mediated toxicity.
Therefore, because JX-795 produces its own IFN-b, addi-
tional tumor selectivity should be achieved without addition
of the cytokine exogenously. This was shown to be the case in
several murine cell lines (Figure 6B); both JX-795 and an
equivalent, IFN-b–negative control virus (carrying deletions
in both B18R and the viral TK gene, but not expressing IFN-b;
TK
 /B18R
 ) could replicate in tumor cell lines to equivalent
levels. However, when the nontransformed NIH 3T3 cell line
was used, viral expression of IFN-b reduced viral replication
by several logs. This also demonstrates a dysfunction in the
type-I IFN response for the murine CMT 64 and JC tumor cell
lines. This ﬁnding was supported by assays of viral gene
expression (Figure 6C). These assays indicated that, although
the B18R and TK gene deletions resulted in approximately a
5-fold reduction in gene expression from nontransformed
cells relative to tumor cells, the addition of IFN-b expression
from this virus resulted in a two-log reduction in viral gene
expression from the nonmalignant cells, without effecting the
ability of the virus to replicate in tumor cells.
IFN-b Gene Expression, Tumor Selectivity, and Efficacy of
JX-795 In Vivo
JX-795 was delivered via tail vein injection to BALB/c mice
bearing established (50–100 mm
3) subcutaneous tumors. In
initial experiments, the concentration of IFN-b in the serum
and in tumors of the animals was assayed (Figure 7A). High
levels of IFN-b were present in the tumors of the treated
animals, but the cytokine appeared to remain localized; only
very small increases in the serum levels of IFN-b were
observed in these animals, which were not sufﬁcient to
produce myelosuppression or transaminitis in the animals
(Table 1), or any overt signs of toxicity, such as signs of
neurotoxicity. Furthermore, bioluminescence imaging (BLI)
was used to determine the biodistribution of viral gene
expression (Figure 7B). The TK-deleted virus infected
Figure 3. Systemic Delivery, Selectivity, and Oncolytic Activity of WR-delB18R Virus
(A) Immunocompetent (BALB/c) mice bearing JC tumors were treated via a single tail vein injection with 1 3 10
8 PFU of vaccinia strains WR or WR-
delB18R. Viral titer (PFU/g) in indicated tissues was determined by plaque assay after sacrifice of animals at indicated time points (n ¼ 3 animals/time
point).
(B) Immunohistochemistry staining for vaccinia coat proteins in tumor tissue sections of animals treated as above and sacrificed 24 h after viral
treatment (magnification 403).
(C) Survival of immunocompetent mice (C57/B6) bearing subcutaneous CMT-93 tumors and treated when tumors reached 50–100 mm
3 with a single
intratumoral (left) or intravenous (right) injection of WR-delB18R or PBS. Doses of 1310
4 (circles), 1310
6 (diamonds), or 1310
8 (triangles) PFU of virus
or PBS controls (squares) were used (n ¼ 5 mice/group; p ¼ 0.0047 for intravenous injections).
doi:10.1371/journal.pmed.0040353.g003
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nontumor tissues within the limbs, abdomen, and head (nasal
and brain) of the treated mice. In contrast, TK
 /B18R
 
double-deleted virus had a more restricted pattern of viral
gene expression. JX-795, however, produced the greatest level
of tumor selectivity with minimal if any gene expression
appearing outside of the tumor. Quantiﬁcation of this signal
indicated that, whereas the TK
 /B18R
  signal remained at
least 10-fold lower than the TK
  signal from 48 h post-
infection onwards, the expression of IFN-b from this strain
further reduced viral nontarget signal by almost two logs, and
signal had returned to background levels by 96 h post-
treatment. Direct correlation between in vivo biolumines-
cence from luciferase-expressing vaccinia and viral replica-
tion in different tissues has been demonstrated previously
[27]. Quantiﬁcation of viral gene expression from within the
tumor target indicated that tumor infection levels were
equivalent for all viruses, despite the marked attenuation of
JX-795 in nonmalignant tissues. JX-795 may therefore be
further used as a gene-delivery vector capable of selectively
expressing further therapeutic transgenes from within the
tumor following systemic delivery.
In order to determine the antitumor effects of the different
viruses, immunocompetent BALB/c mice bearing JC tumors
were treated with a single tail vein injection of 1310
8 PFU of
different viruses or PBS control. JX-795 produced signiﬁ-
cantly greater survival than any other group (p ¼ 0.028), with
three of eight animals displaying complete responses,
demonstrating the additional antitumor beneﬁts of express-
ing IFN-b (Figure 7C).
Discussion
We report here that IFN-b expression from a B18R-deleted
vaccinia results in a systemically effective, highly selective
oncolytic virus. To our knowledge, this is the ﬁrst time that
such a rationally designed combination of attenuating viral
gene deletion and transgene expression has been incorpo-
rated into a systemically deliverable vector, and the ﬁrst
successful report of systemic IFN-b gene delivery to a tumor.
Oncolytic viruses hold promise for the treatment of cancer,
but improvements are needed [2]. In particular, systemic
efﬁcacy against metastatic tumors will be required in order to
have a major impact on cancer patient survival. Novel
approaches are therefore needed to improve intravenous
safety and efﬁcacy [28]. We hypothesized that IFN-b expres-
Figure 4. Potential Mechanisms of Tumor Cell Killing Employed by WR-delB18R
(A) Immunocompetent (C57/B6) mice bearing subcutaneous CMT-93 tumors and treated with a single tail vein injection of 1 3 10
8 PFU of either
psoralen-UV–inactivated WR (IAVV), WR, or WR-delB18R were sacrificed 7 d post-treatment, and CD4-positive cells in tumor sections were scored blind
by a pathologist. Average numbers of positive cells per high-powered field (403) from an average of ten randomly chosen fields from each of three
mice treated under each condition are represented (p¼0.035 for IAVV compared to WR-delB18R treated). An asterisk (*) indicates significantly different
counts.
(B) Mice treated as in Figure 3C and displaying complete responses were rechallenged with a subcutaneous injection of 5 3 10
5 CMT-93 cells. Tumor
burden was measured by calipers (n ¼ 8 mice).
(C) Mice (C57/B6 bearing subcutaneous CMT-93 tumors) were treated with a single tail vein injection of 1310
8 PFU of WR-delB18R virus and sacrificed
after 24 h. Tumor sections stained for viral coat proteins indicated initial infection of tumor vascular endothelial cells (top), whereas tumors from mice
treated as above, but with WR-delB18R expressing GFP (WR-DB18RDTK-GFP), were examined by immunofluorescence following staining with PE-
conjugated antibody targeting CD31 (endothelial cells) (bottom; green ¼ viral GFP expression; red ¼ endothelial cell CD31 staining).
(D) Vascular collapse in tumors of mice treated with WR-delB18R. Subcutaneous CMT-93 tumors implanted into C57/B6 mice were examined by
ultrasound immediately prior to (left) and 48 h after (right) intravenous treatment with 1 3 10
8 PFU WR-delB18R. A nonspecific contrast agent was
delivered intravenously during ultrasound data acquisition in order to detect tumor vasculature (green); the border of the tumor was manually
delineated (red).
doi:10.1371/journal.pmed.0040353.g004
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objectives. First, intravenous delivery of vaccinia viruses
appears to be feasible in immunocompetent animal tumor
models [29,30]. Second, IFN-b antiviral effects in normal
tissues should enhance safety. Finally, IFN-b expression in
tumors should increase efﬁcacy over that mediated by
oncolysis alone.
Because type-I IFNs also possess antiviral properties,
vaccinia has evolved to express both intracellular (K3L, E3L,
and H1L) and extracellular (B18R) gene products that
interfere with type-I IFN activity [20]. In particular, the viral
B18R gene product is secreted from infected cells, binding
and neutralizing extracellular IFN-a and -b [22]. Therefore, to
prevent neutralization of IFN-b after secretion from infected
cancer cells, we deleted the B18R gene from the vaccinia virus
backbone used to express the IFN-b gene.
It appears that the B18R-deleted vaccinia virus (WR-
delB18R) itself is capable of tumor-speciﬁc replication.
Whereas all primary cells tested were capable of inducing
an antiviral state when pretreated with type-I IFN, most (but
not all) cancer cell lines were incapable of responding to this
cytokine. However, when IFN-a was added 5 h postinfection,
to better mimic the likely order of exposure in vivo, wild-
type vaccinia (WR), but not WR-delB18R, was capable of
preventing a subsequent block in viral replication in
susceptible cells. As a result, WR-delB18R was attenuated in
normal cells, but not in most tumor cells, when type-I IFN
was added postinfection; this sequence would be expected to
occur in vivo. Further examination of these effects revealed
that in primary cells, WR-delB18R, like wild-type WR, was
effective at preventing release of IFN-b from infected cells,
but that uninfected neighboring cells could be induced to
produce IFN-b (presumably through TLR binding), and so
induce an antiviral IFN-b response. This antiviral response
could be blocked by expression of B18R or by addition of
anti–IFN-b neutralizing antibody (unpublished data), and
was irrelevant in many cancer cells that were deﬁcient in
their ability to produce (C33A) or respond to (A2780 and
C33A) IFN-b.
The oncolytic potential of WR-delB18R was conﬁrmed in
immunocompetent mice, with the virus rapidly removed
from all tissues other than the tumor, and capable of
producing 100% complete responses after local delivery.
Antitumor effects were also seen following intravenous
delivery, demonstrating the systemic potential of this virus.
However, fewer complete responses were witnessed, indicat-
ing that an increase in tumor cell–killing potential for this
virus (such as by transgene expression) may be needed for
optimal systemic efﬁcacy. Intravenous delivery also exposes
more nonmalignant tissues and organs to the potential of
viral infection, and so tumor-selectivity may become more
critical for this delivery route. Although no toxicity was
observed with WR-delB18R at therapeutic doses, deletion of
intracellular IFN-resistance genes may lead to similar effects
as B18R deletion, and the combination of both deletions may
act together to further attenuate this virus in normal tissues,
if necessary.
This new oncolytic vector was also shown to be capable of
targeting and infecting human colorectal tumor explants ex
vivo, and of destroying tumor cells by multiple mechanisms of
action, one of which, to the best of our knowledge, has not
been previously described. First, cancer-selective replication
results in direct oncolysis. Second, as rechallenge of mice with
tumors following complete responses to treatment resulted in
tumor rejection, it appeared that the virus was capable of
inducing an antitumor immune state within the animal.
Figure 5. Infection of Primary Tumor and Normal Explant Tissues with
B18R- and TK- Deleted Virus Expressing GFP
Three tissue samples (top: rectal tumor with normal rectal tissue; middle:
colon tumor metastases in liver; and bottom: endometrial tumor [no
normal tissue available]:) are represented. Tumor and normal tissue were
mixed with virus, washed, and images taken 48 h later.
doi:10.1371/journal.pmed.0040353.g005
Figure 6. In Vitro Testing of JX-795 (Western Reserve Vaccinia Virus
Containing Deletions of B18R and Thymidine Kinase Genes and
Expressing Luciferase and mIFN-b)
(A) mIFN-b production following infection of human A2780 cells with JX-
795 at an MOI of 5.0. IFN-b secretion into the medium during each hour
postinfection (up to 14 h) was determined by ELISA.
(B) Replication of JX-795 (solid symbols and lines; DB18RDTK-IFNb) and
an equivalent virus (B18R- and TK-deleted, expressing luciferase only;
D18DTK: open symbols; dashed lines) following infection of murine
tumor (CMT-64 [squares] and JC [diamonds]) or nontransformed (NIH
3T3; triangles) cells at an MOI of 1.0.
(C) Viral gene expression (luciferase) as measured by bioluminescence 24
h after infection of indicated cell lines with indicated viruses at an MOI of
1.0, and quantified (average of three experiments).
doi:10.1371/journal.pmed.0040353.g006
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ment was reported previously with HSV [31], but has not been
shown for vaccinia virus. Although the exact mechanisms
have not been proven, they are likely to include recruitment
of antigen-presenting cells, induction of immunostimulatory
cytokines, and release of tumor-associated and viral antigens
following cell lysis, leading to in situ vaccination against the
tumor. Finally, we report the infection of tumor-associated
endothelial cells by the oncolytic virus, resulting in reduced
tumor vascularity. Tumor-associated endothelial cell lysis can
lead to tissue factor release and intratumoral vascular
thrombosis. Endothelial cells are attractive targets for
oncolytic viruses, given their accessibility to infection by
intravascular virus [32]. Tumor-associated endothelial cells
may be speciﬁcally susceptible to this vaccinia mutant for
several reasons [33]. First, these cells tend to be hyper-
proliferative, and therefore may be generally more suscep-
tible to vaccinia infection. Second, epithelial growth factor
(EGF) receptors are frequently expressed on these cells.
Vaccinia replication is enhanced by EGF receptor binding
and activation by vaccinia growth factor (VGF). However,
further research is needed to elucidate the mechanisms
involved and to take full advantage of this novel antitumoral
approach. It will also be interesting to determine whether
tumor–endothelial cell targeting occurs with other vaccinia
virus mutants and/or other oncolytic viruses.
Recombinant IFN-b has been administered systemically for
the treatment of several cancer types. The protein has been
delivered by intramuscular, intravenous, or intratumoral
routes, with common toxicities including myelosuppression,
transaminitis, and neurotoxicity (include seizures), indicating
that localized, tumor-speciﬁc delivery of the cytokine would
be desirable. Antitumoral efﬁcacy was reported, however,
both in patients with brain tumors (including glioblastoma
multiforme) [34,35] and in a patient with colorectal carcino-
ma [36]. IFN-b therefore represents a promising cytokine for
use in cancer therapy. However, because the effects of the
recombinant protein are locally mediated and are short-lived
in vivo, and its systemic administration leads to toxicity,
expression of IFN-b from a gene therapy or oncolytic virus
within the tumor represents a promising means to apply this
cytokine [37]. However, previous approaches have suffered
from a lack of targeted gene delivery [38,39].
The expression of IFN-b from WR-delB18R therefore
represents a promising strategy. Transgene ‘‘arming’’ of
oncolytic viruses has frequently been utilized to enhance
antitumoral efﬁcacy and for noninvasive imaging purposes
[10]. However, in addition to increasing the antitumor
effects of the virus, IFN-b expression serves to further
reduce viral replication in normal tissues. To date, vaccinia
virus–expressed transgenes have not been utilized to inhibit
viral replication and enhance clearance from normal tissues;
Figure 7. In Vivo Testing, Biodistribution, and Efficacy of JX-795
(A) mIFN-b levels were determined by ELISA in the serum, and the tumors of animals (BALB/c bearing subcutaneous JC tumors) treated with (1310
8
PFU) JX-795 (DB18RDTK-IFNb), DB18RDTK virus, or PBS 72 h earlier (n ¼ 3/group).
(B) Biodistribution of viral gene expression (as determined by bioluminescence imaging of mice treated with viruses expressing luciferase). Mice (BALB/
c) bearing subcutaneous JC tumors (arrows) were treated with a single tail vein injection of 1 3 10
8 PFU of viruses, TK-deleted (DTK-luc; squares),
DB18RDTK-luc (triangles), or DB18RDTK-luc-IFNb (JX-795; circles), and imaging performed after luciferin addition. Representative images were taken at
72 h post-treatment. Bioluminescence was quantified over the tumor and the torso of the treated animals (n¼3/group) at times post-treatment (middle
and bottom right-hand panels; symbols are for both graphs).
(C) Survival curves of BALB/c mice bearing subcutaneous JC tumors and treated with a single tail vein injection of 1 3 10
8 PFU of DB18RDTK virus
(diamonds), DB18RDTK-IFNb (JX-795; triangles) or PBS (squares) (p ¼ 0.028 for DB18RDTK relative to DB18RDTK-IFNb).
doi:10.1371/journal.pmed.0040353.g007
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JX-795 for Systemic Cancer Treatment in Micebecause IFN-b has potent antiviral properties, we predicted
viral inhibition would occur in this case. A similar strategy
with IFN-a was recently described for an oncolytic adeno-
virus vector [39]. However, this vector did not demonstrate
systemic delivery or efﬁcacy potential, and efﬁcacy was
limited even with multiple (more than ten) intratumoral
injections. Vector replication and selectivity were not
studied in normal nonimmortalized cells, and no primary
human tissue was tested as reported in this study. Cancer
selectivity was not studied in vivo, either, because tumor-free
animals were studied for toxic effects to the liver only. In
addition, because vaccinia genes expressed from early/late
promoters will be expressed at low levels even during
nonproductive infection of resistant cells, a small amount
of IFN-b will be expressed in any normal tissues exposed to
the virus, allowing the early production of an antiviral state.
Of note, these levels are nontoxic, and high levels of gene
expression are linked tightly to viral replication within
tumor tissue. In this way, transgene expression will be linked
to permissive infection, and thereby restricted to tumor
cells.
The IFN-b gene was inserted into the TK gene, as this
deletion has also been demonstrated to be tumor targeting
[25]. The resulting virus, JX-795, has deletions in both B18R
and TK genes, and expressed IFN-b, as well as luciferase, for
preclinical imaging purposes. It was shown to be highly
speciﬁc for cancer cells in vitro, without the requirement for
addition of exogenous cytokine. JX-795 was also found to
produce high levels of IFN-b in vivo, which remained
localized within the tumor. Viral gene expression was also
highly tumor-restricted in vivo, and so this report represents
the ﬁrst description of a system for the systemic delivery of
type-I IFN to tumors. Furthermore, this virus was capable of
effectively destroying established tumors in mouse models.
We therefore demonstrated that JX-795 is highly tumor
selective and capable of potent antitumor effects in vivo. The
highly tumor-restricted luciferase gene expression seen with
JX-795 indicates that this vector could also be used as a gene-
delivery vehicle for any further therapeutic transgenes whose
expression might lead to toxicity if expressed in any
nonmalignant tissues.
In addition to B18R, vaccinia virus expresses several other
type-I IFN-resistance proteins. These include several intra-
cellular proteins that prevent production of IFN from
infected cells through inhibition of PKR (e.g., E3L and
K3L), or blockade of nuclear factor-jB (NF-jB) activation
and interferon-regulatory factor (IRF) signaling (A52R, A46R,
and N1L). In addition, additional proteins are expressed that
may prevent infected cells from responding to IFN by
blocking STAT1 signaling (H1L) [20]. Future research may
demonstrate that the normal tissue clearance of JX-795 is
further enhanced by deletion of one or more of these genes
or regions within these genes. However, although clearance
from normal tissues is advantageous, overly rapid clearance
from tumor tissue may reduce efﬁcacy. A balance will need to
be achieved for future viruses derived from JX-795.
The rational design of oncolytic viruses combining tumor-
targeting viral deletions with speciﬁc transgenes capable of
complimenting, or even synergizing with, the phenotype of
the attenuated virus represents a promising strategy for the
design of virotherapeutics. In addition, the potential to
destroy the tumor by a multitude of different mechanisms, as
seen with oncolytic vaccinia strains, and the targeting of not
only the malignant cells, but also other cells (e.g., endothelial
and immune cells) within the tumor environment, may be the
most effective approach to applying biological therapies.
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JX-795 for Systemic Cancer Treatment in MiceEditors’ Summary
Background. Normally, throughout life, cell division (which produces
new cells) and cell death are carefully balanced to keep the body in good
working order. But sometimes cells acquire changes (mutations) in their
genetic material that allow them to divide uncontrollably to form
cancers—disorganized masses of cells. Cancers can develop anywhere in
the body and, as they develop, their cells acquire other genetic changes
that enable them to move and start new tumors (metastases) elsewhere.
Chemotherapy drugs kill rapidly dividing cancer cells but, because some
normal cells are also sensitive to these drugs, it is hard to destroy the
cancer without causing serious side effects. Consequently, researchers
are trying to develop ‘‘targeted’’ therapies that attack the changes in
cancer cells that allow them to divide uncontrollably but leave normal
cells unscathed. One promising class of targeted therapies is oncolytic
viruses. These viruses make numerous copies of themselves inside cancer
cells (but not inside normal cells). Eventually the cancer cell bursts open
(lyses), releases more of the therapeutic agent, and dies.
Why Was This Study Done? Existing oncolytic viruses have two major
disadvantages: they have to be injected directly into tumors, and
therefore they can’t destroy distant metastases; and they don’t kill cancer
cells particularly efficiently. In this study, the researchers have tried to
adapt vaccinia virus (a virus that infects humans and which has recently
been shown to kill tumor cells when injected into the bloodstream) in
two ways: to both infect cancer cells selectively and then to kill them
effectively.
They hypothesized that putting a gene that causes expression of a
protein called interferon-beta (IFN-b) in a particular virus strain that is
itself incapable of responding to IFN-b might achieve these aims. Human
cells infected with viruses usually release IFNs, which induce an antiviral
state in nearby cells. But vaccinia virus makes anti-IFN proteins that
prevent IFN release. If the viral genes that encode these proteins are
removed from the virus, the virus cannot spread through normal cells.
However, many cancer cells have defective IFN signaling pathways so the
virus can spread through them. IFN-b expression by the virus, however,
should improve its innate anticancer effects because IFN-b stops cancer
cells dividing, induces an antitumor immune response, and stops tumors
developing good blood supplies.
What Did the Researchers Do and Find? The researchers selected a
vaccinia virus strain called WR-delB18R in which the B18R gene, which
encodes an anti-IFN protein, had been removed from the virus. (WR is a
wild-type virus.) In laboratory experiments, IFN treatment blocked the
spread of WR-delB18R in normal human cells but not in human tumor
cells. After being injected into the veins of tumor-bearing mice, WR-
delB18R was rapidly cleared from normal tissues but persisted in the
tumors. A single injection of WR-delB18R directly into the tumor killed
most of the tumor cells. A similar dose injected into a vein was less
effective but nevertheless increased the survival time of some of the
mice by directly killing the tumor cells, by targeting the blood supply of
the tumors, and by inducing antitumor immunity. Finally, when the
researchers inserted the IFN-b gene into this WR-delB18R, the new
virus—JX-795—was much better at killing tumors after intravenous
injection than either WR or WR-delB18R.
What Do These Findings Mean? These findings indicate that the
vaccinia virus can be adapted so that it replicates only in tumor cells and
kills these cells effectively after intravenous injection. In particular, they
show that the strategy adopted by the researchers both optimizes the
anticancer effects of the virus and minimizes viral replication in normal
tissues. JX-795 is a promising oncolytic virus, therefore, particularly since
vaccinia virus has been safely used for many years to vaccinate people
against smallpox. Nevertheless, it will be some years before JX-795 can
be used clinically. Vaccinia virus constructs like this need to be tested
extensively in the laboratory and in animals before any attempt is made
to test them in people and, even if they passes all these preclinical tests
with flying colors, only clinical trials will reveal whether they can treat
human cancer. Several related strains of vaccinia virus are currently
undergoing clinical testing.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/:10.1371/journal.pmed.
0040353.
  The US National Cancer Institute provides information on all aspects of
cancer (in English and Spanish)
  CancerQuest, from Emory University, provides information on all
aspects of cancer (in several languages)
  The UK charity Cancerbackup also provides information on all aspects
of cancer
  Wikipedia has a page on oncolytic viruses (note that Wikipedia is a free
online encyclopedia that anyone can edit; available in several
languages)
  A short interview about oncolytic viruses with researcher Dr. John Bell
is available on the Insidermedicine Web site
  The Oncolytic virus Web page provides lists of oncolytic viruses
classified by type
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